HD-OPM Archive

Statin side effects: what's real, what's nocebo, and what to do

Which statin side effects are genuinely caused by the drug (muscle, blood sugar, liver), how often they occur according to large blinded trials, why so many reported symptoms are not drug-caused, and what the group's admins suggest trying if you feel unwell on a statin.

15 min read43 group posts cited30 studies discussed2 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • "In a pooled analysis of 19 blinded trials (123,940 people), muscle pain or weakness was reported by 27.1 in 100 on a statin and 26.6 in 100 on placebo over about four years, so only a small fraction of muscle complaints is drug-caused.1"
  • "In the SAMSON n-of-1 trial, about 90% of the symptom burden people attributed to statins also occurred on placebo; roughly 10% was pharmacological.23"
  • "The Lancet CTT meta-analysis of 23 double-blind trials (over 154,000 participants) found no causal link for 62 of 66 side effects listed on statin labels.4"
  • "The diabetes signal is real but small: about 1 extra case per 255 people treated for 4 years, versus 5.4 cardiovascular events prevented, and it is concentrated in people who already have metabolic risk factors.56"
  • "Significantly raised creatine kinase, rhabdomyolysis and lasting liver injury are uncommon; if symptoms are bothersome, lowering the dose, switching statins or using a non-statin drug are the options the admins describe.789"
In this summary
  1. What "statin side effects" actually covers
  2. What the evidence shows
  3. Nuances, controversies and common misconceptions
  4. Managing side effects: what the group suggests
  5. What this means for you
  6. Frequently asked questions
  7. The evidence behind this summary

Statins do have genuine side effects, but they are far less common than most people think. Large blinded trials suggest that the majority of muscle aches, memory complaints and other symptoms reported on statins also appear in people taking a dummy pill. What is real, according to the group's posts, is a modest rise in muscle symptoms (mostly in the first year), a small nudge in blood sugar, and a small rise in liver blood tests.410

That does not mean your symptoms are imaginary. The group's admins stress that nocebo symptoms are "very real" but generated by expectation rather than by the drug itself, and that anyone can be fooled, including Louis Nervegna himself.1112 Because the two feel identical from the inside, the posts below focus on how to tell them apart and what to do about each.

This article summarizes what the group's posts say. It is a reading guide to the evidence the admins have collected, not personal medical advice; where the posts give an opinion, it is attributed.

27.1 vs 26.6in 100 people reported muscle pain or weakness on a statin versus placebo in 19 blinded trials1
1 in 15muscle complaints in the first year on a statin was actually caused by the statin1
62 of 66side effects listed on statin labels showed no causal link in blinded trials4
1 per 255people treated for 4 years got diabetes because of the statin, while 5.4 cardiovascular events were prevented5

What "statin side effects" actually covers

A few terms come up repeatedly.

  • Myalgia is muscle pain or aching. It is distinct from muscle atrophy (wasting), and Louis notes that myopathy severe enough to cause atrophy is very rare on statins.13
  • Myopathy is a muscle disease; in the group's usage, true myopathy is rare while benign aches are fairly common.14
  • Rhabdomyolysis is severe muscle breakdown. Louis puts it at about 1 in 100,000 statin users, or perhaps 1 in 10,000 if being conservative.1315
  • Creatine kinase (CK) is a "muscle enzyme" measured in blood. A significant rise is an objective sign of muscle injury.7
  • Nocebo effect is the mirror image of placebo: expecting harm from a pill produces real physical symptoms generated by the mind, not by the pill.12

Part of the confusion is that reported rates depend on how you count. One video the admins shared notes that reported muscle symptoms on statins range from 1% to 25% depending on the definition.211 A pharmacology-focused summary Louis reposted says roughly 22% of statin patients have some musculoskeletal pain.16

What the evidence shows

The big picture: the CTT meta-analysis

The most comprehensive assessment the group has shared is a Lancet analysis (published online in February 2026) from the Cholesterol Treatment Trialists (CTT) Collaboration. It used individual participant data from 23 large double-blind randomized trials: 123,940 participants in 19 statin versus placebo trials, plus 30,724 in four trials of more versus less intensive statin therapy, followed for a median of nearly five years.10 It looked only at events listed on statin product labels.4

Of 66 label-listed outcomes, 62 showed no causal association. The ones that did were mild liver enzyme elevations (dose-dependent and clinically small), small changes in urine composition, oedema, and the already-known effects on muscle symptoms and new-onset diabetes.4 Reports of the following were similar on statin and placebo: memory loss or dementia, depression, sleep disturbance, erectile dysfunction, weight gain, nausea, fatigue and headache.10

The Oxford investigator quoted in a New Scientist report said "we can now be confident" that statins do not cause the vast majority of the issues listed in patient leaflets, and the report mentions calls to update statin packaging warnings.17 An essay urging over-the-counter statins, which Louis quoted, puts serious muscle injury at under 0.1% of users and liver toxicity about an order of magnitude rarer (0.01%).18

Muscle symptoms and the nocebo effect

Muscle pain is the side effect people worry about most, and the group has collected several lines of evidence.

SAMSON (n-of-1 trial). People who had stopped statins because of side effects received four one-month bottles of a statin, four of placebo and four empty bottles, in random order.19 Symptom intensity on placebo and on the statin were similar, and both were significantly greater than in the no-tablet months.3 About 60 patients took part; roughly 90% of the symptom burden attributed to statins also occurred on placebo, and about 10% was pharmacological.2 Half of the participants were able to restart statins.19 The study was published in NEJM in 2020.19

ASCOT. The shared video also cites ASCOT data in which side-effect reports jumped 41% when patients learned they were on a statin rather than a placebo.211

Pooled blinded trials. A pooled analysis of 19 blinded trials with 123,940 people found muscle pain or weakness in 27.1 per 100 on a statin versus 26.6 per 100 on placebo over about four years. In the first year, only about 1 in 15 muscle complaints among statin users was caused by the statin.1 The CTT summary Louis quoted similarly says statins caused muscle symptoms in only about 1% of people in the first year of treatment, with no excess thereafter.10

Louis summarizes this as "up to 90%" of statin side effects being nocebo, while insisting that real side effects exist and should not be minimized.811 Dr. Michael Richman, a cardiothoracic surgeon whose video Louis shared, makes the same point about why muscle pain is so readily blamed on the medicine.20

STOMP (performance). In a 6-month, double-blind trial of 420 healthy adults, atorvastatin 80 mg did not impair strength, VO2 max, endurance or physical activity across 14 measures. Muscle pain was twice as common on the statin than on placebo (9.4% vs 4.6%) but did not measurably change performance. The trial was short, in healthy adults and with one statin, so it may not generalize.21

Blinded trials: muscle complaints are common on placebo tooShare of people reporting muscle symptoms on a statin versus placebo in two kinds of blinded trial
StatinPlacebo
Muscle pain or weakness, 19 pooled trials (123,940 people)27.1%26.6%
Muscle pain, STOMP (atorvastatin 80 mg, 420 healthy adults)9.4%4.6%
Different studies and definitions: the pooled analysis followed patients for about four years; STOMP gave healthy adults the top dose for six months and found no loss of strength or endurance. Source: 121
Show data
StatinPlacebo
Muscle pain or weakness, 19 pooled trials (123,940 people)27.1%26.6%
Muscle pain, STOMP (atorvastatin 80 mg, 420 healthy adults)9.4%4.6%

When muscle problems are real

Louis is clear that some muscle problems are genuine.

  • Elevated CK. Nocebo does not raise CK "as far as I am aware," he says. If a significantly raised CK persists after exercise, infection, trauma and hypothyroidism are excluded, the statin is the likely cause. This is uncommon, more serious than ordinary myalgia, and usually prompts a physician to stop the statin or lower the dose with close monitoring.7 Louis assumed for illustration that about 0.2% of users have significant CK elevations.7
  • Genetics. Louis argues that statin-related muscle pain in susceptible people is genetic. He shared an Atlantic article proposing that people at higher risk likely carry variants in genes coding for HMG-CoA reductase (the enzyme statins block), and that extreme versions of the same defects cause a rare muscle disorder, limb girdle muscular dystrophy.822 The shared source is journalism rather than a primary paper, and Louis hopes for a future genetic test.1322

Diabetes

The statin-diabetes link is established, but the group's posts consistently describe it as small in absolute terms.

  • A meta-analysis of 13 trials (91,140 patients) found that treating 255 people with statins for 4 years led to 1 extra case of diabetes while 5.4 cardiovascular events were prevented.5 Gokhan's review gives the relative increase as about 9% (OR 1.09), with intensive-dose therapy about 12% higher than moderate-dose.6
  • Louis cites roughly 5-year trials showing a 9% to 12% relative increase, and 20% to 36% for very high-intensity regimens. He deliberately framed this in the scariest way: if your 5-year diabetes risk is 1 in 1,000 it rises to about 1.12 in 1,000, whereas someone at 1 in 2 could be nudged over the diagnostic threshold.23
  • In JUPITER (rosuvastatin 20 mg, about 17,600 people), statin allocation brought the diagnosis of diabetes forward by an average of 5.4 weeks and raised HbA1c by about 0.1 point at 24 months. Louis reads this as "no one got diabetes who was not going to get it anyway," and the underlying Lancet analysis concluded benefits exceeded the diabetes hazard even in people at high risk.24 JUPITER also showed a 44% reduction in heart attacks and strokes.5 Gokhan's review notes a 26-27% increase in physician-reported diabetes in that trial.6
  • Who is affected: excess cases occur almost exclusively in people with baseline risk factors such as impaired fasting glucose (100-125 mg/dL), BMI over 30, metabolic syndrome or HbA1c over 6%; with normal glycemic markers and body weight the risk is described as negligible.623
  • Genetics: Louis shared a Gemini-assisted post arguing that genetic variants that mimic statin and ezetimibe targets also show modestly higher glucose and diabetes risk, suggesting the effect is tied to LDL lowering itself rather than an off-target toxicity.25
Diabetes risk rises with statin intensityRelative increase in new-onset type 2 diabetes in randomized trials lasting about 5 years
Usual statin regimens+9 to +12%
Very high-intensity regimens+20 to +36%
Relative increases. Louis's example: a 1 in 1,000 five-year diabetes risk becomes about 1.12 in 1,000. Source: 23
Show data
Value
Usual statin regimens+9 to +12%
Very high-intensity regimens+20 to +36%
The mitigation table from the review Gokhan posted: lifestyle change for everyone, pitavastatin for people with prediabetes, a moderate-intensity statin plus ezetimibe or a PCSK9 inhibitor for higher-risk patients, and regular HbA1c or glucose checks in metabolic syndrome.
The mitigation table from the review Gokhan posted: lifestyle change for everyone, pitavastatin for people with prediabetes, a moderate-intensity statin plus ezetimibe or a PCSK9 inhibitor for higher-risk patients, and regular HbA1c or glucose checks in metabolic syndrome.6

Louis also points out that a ketogenic diet reduces muscle insulin sensitivity temporarily and to a much larger degree than statins do, and that both effects reverse on stopping.26

Liver

Rises in liver enzymes are among the small number of effects the CTT analysis confirmed, but they were clinically small: about 0.1% more liver blood-test abnormalities, with no increase in hepatitis or liver failure.410 Louis quotes Harvard Health: about 1 in 1,000 statin users have an abnormal liver test attributable to the drug, abnormal results are about as common on placebo in some studies, and serious liver injury is rare and tends to occur in people who already have liver disease or take other interacting medications.2728 That source recommends one baseline liver test before starting and says routine repeat monitoring is not useful for most people.27 Louis adds that short-term enzyme rises usually resolve within weeks to months.28

A 2017 review Louis shared suggests statins may even benefit some chronic liver disease, though the authors say randomized trials are needed to confirm this.29

Memory, testosterone and sexual function

Beyond the CTT finding of 0.2% per year memory-complaint reports on both statin and placebo10, Louis cites a meta-analysis of 55 studies in over 7 million people linking statin use to lower dementia risk, and notes the PREVENTABLE trial of about 20,000 older adults is testing this directly.514 He adds that those worried about memory can choose rosuvastatin, which crosses the blood-brain barrier poorly.5

A post by Gokhan reports that meta-analyses show statins lower total testosterone by about 9-13 ng/dL against a normal range of 300-1,000 ng/dL, and that statins often improve erectile function scores in men with high cholesterol.30

How often the real effects occur

The frequencies quoted in the posts, side by side:

EffectHow often, as reported in the posts
Muscle symptoms caused by the statinAbout 1% of people, in the first year only10
Significant creatine kinase (CK) riseAbout 0.2% of users, Louis's illustrative assumption7
Serious muscle injuryUnder 0.1% of users18
RhabdomyolysisAbout 1 in 100,000 users, or 1 in 10,000 to be conservative1315
Abnormal liver test attributable to the drugAbout 1 in 1,000 users27
Liver toxicityAbout 0.01% of users18
New diabetes1 extra case per 255 people treated for 4 years5

Nuances, controversies and common misconceptions

"90% nocebo" is a headline, not a law. The 90% figure comes from SAMSON, which enrolled about 60 people who had already quit statins.2 The very large pooled analyses give a related but differently framed number: about 1 in 15 muscle complaints caused by the statin in year one.1 STOMP found muscle pain doubled on high-dose atorvastatin.21 These are best read together: most complaints are not drug-caused, but a minority are.

Real versus mind-made. Nocebo symptoms are not faked. Both the admins and the shared video say the aches and fatigue are real.211 Louis says he was fooled himself, and he suggests taking testimonials from people prone to conspiratorial thinking about medicine with a grain of salt.1119 Tim Spector, whose Telegraph account Louis shared, avoided statins for nearly a decade, then had a mini-stroke at 53 and said his muscle cramps had been nocebo.31

Mechanism claims are mostly hypotheses. Louis argues that statins cause beneficial mild mitochondrial stress (mitohormesis) via AMPK activation and may help sarcopenia (age-related muscle loss).131532 A 2025 review he shared calls this promising,33 but a Medical Hypotheses paper he cited is explicitly a hypothesis, and the posts present no randomized human trial showing a muscle benefit.15

Real individual experience matters. Gokhan reported that atorvastatin made him feel "spaced out" and "off" at every dose, while rosuvastatin was uneventful. He later added ezetimibe, then moved to pitavastatin 1 mg and Repatha and says he feels well. This is anecdote, not evidence.34

Alternatives are not free of side effects. Louis notes that PCSK9 inhibitors such as Repatha list flu-like symptoms, back pain and high blood sugar as common effects, and that their long-term safety record is shorter.35 He personally takes a low-dose statin because statin side effects are "known unknowns" after decades of study, while newer drugs have "unknown unknowns." This is his opinion.36 Even niacin, which Louis says can lower Lp(a), adds no outcome benefit on top of high-dose statins in two large trials while increasing side effects.37

Dropping a statin has a cost. In the STREAM trial of 1,880 adults aged 70 and older without known cardiovascular disease, those who stopped statins had 12.7% heart attack, ischemic stroke or death versus 9.2% on continued statins, about 38% more events in relative terms. The trial was called noninferior, but the commentary Louis shared stresses that this only means the difference fell inside a preset margin, that stopping did not meaningfully improve muscle pain, quality of life, falls or sarcopenia, and that the safety board advised discussing restarting. Stopping can be appropriate based on frailty, life expectancy, adverse effects or individual risk, but not simply because of age.38

Managing side effects: what the group suggests

The admins' suggestions, in rough order:

  1. Check it is not something else. For raised CK, rule out exercise, infection, trauma and hypothyroidism.7
  2. Consider nocebo honestly. Louis urges ruling it out before blaming the drug.811
  3. Lower the dose rather than quitting. Citing a Tom Dayspring slide, Louis shows diminishing returns: atorvastatin 10 mg lowers LDL about 37%, 20 mg 43%, 40 mg 48% and 80 mg 51%. Moving from 10 mg to 80 mg adds only about 14 more percentage points. He suggests lowering LDL with diet and lifestyle first, then using the lowest effective dose.9
  4. Try another statin. Many people who get myalgia on one statin tolerate another; he names pitavastatin and pravastatin, and says switching from lipophilic to hydrophilic statins often helps.813
  5. Use non-statin LDL-lowering drugs if needed. A moderate-intensity statin plus ezetimibe lowered LDL similarly to a high-intensity statin with significantly fewer muscle symptoms in patients 70 and older (NEJM summary).39 In a small study of 33 statin-intolerant patients, ezetimibe three times a week cut LDL-C about 20%, and 85% tolerated it.40 A bempedoic acid trial in 4,206 statin-intolerant primary-prevention patients showed a 30% reduction in its primary composite outcome and 27% lower all-cause mortality, with more gout and gallstones.41
  6. Check vitamin D. Louis suggests supplementing if levels are low, citing a small 6-month pilot in which 64% of vitamin D-deficient, statin-intolerant patients tolerated a statin re-challenge after correction. It is a pilot, not a definitive trial.16
  7. CoQ10 is optional. Louis says it is harmless and may offset statin-lowered CoQ10, but most trials for statin muscle pain failed.8 A summary he shared says the best-designed trials show no benefit and muscle levels barely change.42
  8. Watch interactions. Grapefruit juice and some herbs and botanicals can raise statin levels through cytochrome P450; the grapefruit interaction applies only to certain statins.43
From the CoQ10 summary Louis shared: in placebo-controlled trials statins consistently lowered CoQ10 in the blood, but in most muscle biopsy studies muscle CoQ10 did not change.
From the CoQ10 summary Louis shared: in placebo-controlled trials statins consistently lowered CoQ10 in the blood, but in most muscle biopsy studies muscle CoQ10 did not change.42

What this means for you

  • The group's admins recommend discussing any new muscle pain or persistent weakness with your doctor rather than stopping or continuing on your own; a CK test is how a real muscle problem is separated from nocebo.7
  • If symptoms are mild, a lower dose or a different statin often keeps most of the LDL benefit.89
  • If you have prediabetes, obesity or metabolic syndrome, the diabetes nudge is most relevant to you, and the posts still describe cardiovascular benefit as outweighing it.624
  • Do not assume a drug alternative is automatically safer; each has its own side-effect profile.3541
  • Before stopping altogether, ask about the dose, switching and non-statin options, and about how stopping would change your risk.3138
  • Liver testing: one baseline test, then routine repeat testing is generally unnecessary unless you are at high risk.27

Frequently asked questions

Does a statin cause muscle pain?

Sometimes. In pooled blinded trials, 27.1% on a statin and 26.6% on placebo reported muscle pain or weakness over about four years.1 High-dose atorvastatin did double pain in healthy volunteers in STOMP (9.4% vs 4.6%).21

How do I know if it is nocebo or real?

Louis notes SAMSON-style blinded re-challenge is how researchers separated them,19 and that a significantly raised CK after other causes are excluded points to a real effect.7

Will statins give me diabetes?

Mainly if you were already close to it. The 13-trial analysis found 1 extra case per 255 people over four years versus 5.4 cardiovascular events prevented.56

Should I have regular liver tests?

Harvard Health, as quoted by Louis, recommends one baseline test and says routine monitoring is not a good use of money and time.27

Can I take CoQ10 or vitamin D to prevent side effects?

CoQ10 has not reliably worked in trials.42 Low vitamin D has been linked to statin myalgia and correcting it helped some in a small pilot.16

Do statins cause memory loss?

The CTT analysis found memory-complaint reports at 0.2% per year on both statin and placebo.10

The evidence behind this summary30 studies · 7 meta-analyses · 9 trials · 1 MR

The 43 group posts cited above discuss 30 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 7Randomized trials 9Mendelian randomization 1Reviews & guidelines 6Animal & lab studies 2Other sources 5

Strongest evidence discussed

All 30 studies and sources
Sources from the group (43)
  1. Pooled blinded trials: statins cause only about 1 in 15 reported muscle aches Louis Nervegna · Oct 23, 2026 · Facebook
  2. SAMSON trial: 10% of statin symptom burden was pharmacological, the rest nocebo Louis Nervegna · Apr 28, 2026 · Facebook
  3. Nocebo effect explained about 90% of symptoms in patients who quit statins (SAMSON trial) Louis Nervegna · Apr 15, 2024 · Facebook
  4. CTT meta-analysis: of 66 label-listed statin side effects, 62 showed no causal link Louis Nervegna · Feb 08, 2026 · Facebook
  5. What cardiologists say about statins: dementia, muscle pain, diabetes, primary prevention Louis Nervegna · Jan 13, 2026 · Facebook
  6. Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist Gokhan Can · Nov 26, 2025 · Facebook
  7. Elevated creatine kinase on a statin means muscle symptoms are real, not nocebo Louis Nervegna · Apr 29, 2026 · Facebook
  8. What to try for statin muscle pain: lower dose, other statins, non-statins; beware nocebo Louis Nervegna · Feb 17, 2025 · Facebook
  9. Most of a statin's LDL lowering comes from low doses; cut the dose rather than quit Louis Nervegna · Jan 24, 2025 · Facebook
  10. Statins: 0.2% yearly memory complaints on statin and placebo alike in Lancet CTT analysis Louis Nervegna · Feb 06, 2026 · Facebook
  11. Up to 90% of statin side effects occur on placebo too (SAMSON and ASCOT) Louis Nervegna · Apr 28, 2026 · Facebook
  12. The nocebo effect can produce real symptoms from believing a pill is harmful Louis Nervegna · Oct 27, 2024 · Facebook
  13. Statin muscle pain is common in some, severe damage is rare; statins may aid sarcopenia Louis Nervegna · Jan 02, 2025 · Facebook
  14. Serious statin muscle side effects (myopathy) are rare; benign aches are common Louis Nervegna · Jun 29, 2026 · Facebook
  15. Statin muscle toxicity overstated: rhabdomyolysis ~1 in 100,000; sarcopenia use studied Louis Nervegna · Dec 16, 2024 · Facebook
  16. Low vitamin D tied to statin myalgia; correcting it let 64% retry statins in a pilot Louis Nervegna · Jun 15, 2025 · Facebook
  17. New Scientist: most statin label side effects are not caused by statins Louis Nervegna · Feb 11, 2026 · Facebook
  18. Case for over-the-counter statins: 22% lower risk per 1 mmol/L LDL drop Louis Nervegna · May 19, 2025 · Facebook
  19. N-of-1 trial: most statin side effects arose with placebo too, pointing to nocebo Louis Nervegna · Feb 24, 2025 · Facebook
  20. Most statin muscle pain is a nocebo effect, per the SAMSON trial Louis Nervegna · Aug 01, 2026 · Facebook
  21. STOMP: atorvastatin 80 mg for 6 months did not impair muscle strength (n=420) Louis Nervegna · Jun 11, 2026 · Facebook
  22. Statin muscle side effects may stem from HMG-CoA reductase gene variants Louis Nervegna · May 03, 2024 · Facebook
  23. Statins raise type 2 diabetes risk 9-12% relative, a tiny absolute effect for most people Louis Nervegna · May 25, 2026 · Facebook
  24. In JUPITER, rosuvastatin brought diabetes diagnosis forward by only 5.4 weeks Louis Nervegna · Feb 13, 2024 · Facebook
  25. Genetics suggest statins' small diabetes risk is tied to LDL lowering (Gemini-assisted) Louis Nervegna · Sep 07, 2026 · Facebook
  26. Keto causes bigger temporary insulin resistance than statins, so statin fear is overplayed Louis Nervegna · Sep 16, 2024 · Facebook
  27. Serious liver problems from statins are rare and routine liver monitoring is unnecessary Louis Nervegna · Feb 23, 2025 · Facebook
  28. Statin-related liver enzyme elevations are rare (about 1 in 1,000) and usually transient Louis Nervegna · Apr 03, 2026 · Facebook
  29. Statins may benefit chronic liver disease rather than harm it, per a review Louis Nervegna · Jul 16, 2024 · Facebook
  30. Statins lower testosterone only slightly and often improve erectile function Gokhan Can · Jan 03, 2026 · Facebook
  31. Tim Spector had a mini stroke at 53 and now takes statins Louis Nervegna · Jul 09, 2026 · Facebook
  32. Statins activate AMPK via mild mitochondrial stress, which Louis argues is beneficial Louis Nervegna · Nov 23, 2023 · Facebook
  33. Statins are being studied as a treatment for sarcopenia Louis Nervegna · Nov 17, 2025 · Facebook
  34. Admin's experience adding ezetimibe, pitavastatin and Repatha after statin intolerance Gokhan Can · Jan 08, 2026 · Facebook
  35. PCSK9 inhibitors like Repatha have real side effects and a shorter safety record Louis Nervegna · Apr 15, 2024 · Facebook
  36. Why Louis takes a low-dose statin: known side effects beat unknown ones of newer drugs Louis Nervegna · May 09, 2024 · Facebook
  37. Niacin can cut Lp(a) (one member saw 40% with 1500 mg) but has no outcome proof Louis Nervegna · Jan 19, 2024 · Facebook
  38. STREAM: why 'noninferior' does not make stopping statins at age 70 safe Louis Nervegna · Nov 15, 2026 · Facebook
  39. Moderate statin plus ezetimibe matched high-intensity LDL drop with less myalgia at 70+ Louis Nervegna · May 13, 2025 · Facebook
  40. Thrice-weekly ezetimibe cut LDL-C 20% in 33 statin-intolerant patients Gokhan Can · Sep 22, 2025 · Facebook
  41. Bempedoic acid cut CV events and may also dampen age-related inflammation Louis Nervegna · Jul 21, 2026 · Facebook
  42. CoQ10 supplements do not reliably prevent statin muscle symptoms Louis Nervegna · Apr 16, 2026 · Facebook
  43. Supplements and foods can raise statin levels through cytochrome P450 interactions Louis Nervegna · Dec 01, 2023 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary